Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.06%
#3 CoW Protocol CoW Protocol +41.78%
#4 Glidr Glidr +36.87%
#5 Humanity Humanity +26.87%
#6 Codatta Codatta +21.56%
#7 Walrus Walrus +20.27%
#8 Enso Enso +18.27%
#9 The Black Bull The Black Bull +16.62%
#10 Tutorial Tutorial +14.28%
Coin of the day
EXOD EXOD
Cài đặt
Ngôn ngữ
TIếNG VIệT
Tiền tệ
USD
Chủ đề
CASI Pharmaceuticals, Inc. CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc.

CASI
Xếp hạng trong cổ phiếu #36784
CASI Pharmaceuticals, Inc. is a biopharmaceutical firm focused on the... CASI Pharmaceuticals, Inc. is a biopharmaceutical firm focused on the development and market introduction of medical treatments and drugs across China, the United States, and globally. Its marketed product, EVOMELA, is an intravenous formulation of melphalan, utilized for conditioning prior to stem cell transplantation and as a palliative option for patients suffering from multiple myeloma. The company's developmental pipeline encompasses several experimental therapies. This includes CNCT19, an investigational autologous CD19 CAR-T therapy aimed at treating patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). BI-1206 is currently in Phase I/II trials, combined with the anti-PD1 therapy Keytruda, for solid tumors, and is also undergoing a Phase I/IIa study in conjunction with MabThera (rituximab) for individuals with relapsed/refractory NHL. CB-5339 is advancing through Phase I clinical trials for acute myeloid leukemia and myelodysplastic syndrome. Further additions to its pipeline are CID-103, targeting multiple myeloma patients, and Thiotepa, which possesses a broad range of indications, including its use as a conditioning therapy for various allogeneic hematopoietic stem cell transplants. Additionally, long-acting injectable formulations of Octreotide are being developed for managing acromegaly and alleviating symptoms associated with different neuroendocrine tumors. CASI maintains licensing agreements with Juventas Cell Therapy Ltd, BioInvent International AB, Black Belt Therapeutics Limited, and Cleave Therapeutics, Inc. It has also forged distribution partnerships with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd, Pharmathen Global BV, and Riemser Pharma GmbH. Incorporated in 1991, this Rockville, Maryland-based company was formerly known as EntreMed, Inc. before adopting its current name, CASI Pharmaceuticals, Inc., in June 2014.
Giá cổ phiếu
$0.15
Đồng bộ lần cuối: 2026-04-13
Vốn hóa thị trường
$2.33M
Thay đổi (1 ngày)
3.88%
Thay đổi (1 năm)
-93.70%
Quốc gia
CN
Giao dịch CASI Pharmaceuticals, Inc. (CASI)

Danh mục

Healthcare
Lịch sử giá cổ phiếu của CASI Pharmaceuticals, Inc. (CASI)
Giá đóng cửa cao nhất: $0.14 vào 2026-04-01

Giá đóng cửa thấp nhất: $1.67K vào 1996-06-01
Lịch sử giá cổ phiếu của CASI Pharmaceuticals, Inc. từ 1996 đến 2026
Hiệu suất giá cổ phiếu hàng năm
Năm Hiệu suất
2026 (TTM) 32.52%
2025 -72.44%
2024 -53.46%
2023 283.37%
2022 -79.05%
2021 -68.42%
2020 -16.54%
2019 -24.32%
2018 30.06%
2017 155.84%
2016 26.21%
2015 -27.36%
2014 -14.44%
2013 12.11%
2012 11.08%
2011 -77.05%
2010 -43.19%
2009 302.44%
2008 -82.88%
2007 -24.57%
2006 -17.29%
2005 -25.64%
2004 -20.23%
2003 227.92%
2002 -87.78%
2001 -56.55%
2000 -23.06%
1999 11.82%
1998 101.68%
1997 -19.22%
1996 0.00%
Giá cổ phiếu của các công ty hoặc đối thủ tương tự
Công ty Giá cổ phiếu Thay đổi 1năm% Quốc gia
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $505.24 28.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $846.09 29.41%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $731.69 6.47%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 $1.07K -6.40%
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $251.82 11.75%
BE